Home » Newsletters » BioWorld

BioWorld

June 29, 2004

View Archived Issues

Amgen's GDNF Misses In Phase II Parkinson's Trial

Amgen Inc.'s therapy for Parkinson's disease failed to meet its primary endpoint in a Phase II study. (BioWorld Today) Read More

Virogenomics New Spin-Off Artielle: $11M For MS Work

Alteon's Stock Sale Raises Up To $12.8M For Phase IIs

LSBC, University Of Louisville Join Up To Develop HPV Drugs

Other News To Note

Appointments And Advancements